Biogen (BIIB) PT Lowered to $333 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $253.14 +0.35%
Rating Summary:
30 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
30 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
Baird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $333.00 (from $340.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- TMX Group (X:CN) (TMXXF) PT Raised to Cdn$67 at TD Securities
- Brown & Brown (BRO) PT Lowered to $85 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
